Attend Biomarkers & Precision Medicine

Together we achieve more
For every patient who hopes for a better outcome

What is Biomarkers & Precision Medicine

Targeted therapies are reframing the outlook for human health creating unprecedented scope for life-changing targeted treatments.

Are you ready to participate in this shared opportunity? Do you have the knowledge, strategy, tools and connections in place?

Precision Medicine provides the platform for you to learn, engage and collaborate across the entire targeted therapy R&D ecosystem — an interdisciplinary community of specialists in pharma, biotech, academia and healthcare.

Biomarkers & Precision Medicine UK, takes place on September 30-1 October in London, UK. Running across two full days, with 16 tracks across three dedicated programmes it's the must attend event for those involved in bringing next-generation personalized treatments to market

What is Biomarkers

The Event in Numbers

1000

leading pharma, biotech, regulatory & academic delegates

200
hours of pre-arranged 1-2-1 meetings, facilitating business growth
30
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments

Why attend?

Expand your knowledge
Let subject specialists take you further and deeper.
With comprehensive learning in oncology, neuroscience and key complementary areas.

Build the partnerships you need
Identify, meet and collaborate with the people your strategy requires.
Start working with those who share your goals with 200 hours of pre-arranged 1-2-1s.

Join the conversation
Meet like-minded peers, expand your network and engage in interdisciplinary discussion on the latest thinking and practice.

See what’s in the pipeline
Our events are where innovations land.
Be at the showcase and meet the people behind technologies to give you the edge. 

Understand the competitive landscape
Learn what others in your field are doing.
Evaluate their successes (and failures) and set your own benchmarks. 

Harness AI & machine learning
AI & machine-learning tools will be critical in unlocking growth.
See the technology in action and speak to those who can help you implement it.

Why Attend Photos

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful private roundtables, to an exclusive gala dinner. Discover the moments that will transform your NextGen Omics & Spatial experience. 

Precision Medicine Awards 2025 Logo (Light)

Join us at the Precision Medicine Awards 2025, for an evening dedicated to celebrating visionary institutions and individuals who are driving innovation & excellence in Precision Medicine. Held at the stunning Grade II listed Assembly Hall at Church House - just a 3 minute walk from the conference venue - this prestigious event offers a unique timely opportunity to celebrate and honour groundbreaking achievements in the industry which are accelerating targeted treatments and transforming patient outcomes. 

Event Experience

Networking & knowledge-sharing is at the heart of what we do, with 200+ hours of pre-arranged 1-2-1 meetings and over 12 hours of facilitated networking solutions don't miss the opportunity to connect with 1,000 leaders from across pharma, biotech, regulatory and academia.

Engaging Thought Leadership
Hear from industry leaders on key developments and pain points in the advancement of precision medicine within a variety of interactive discussions.

Global Technology Showcase
An international exhibition showcasing cutting-edge technologies & services from premier providers in the scientific field.

Networking Emphasis
Unparalleled networking opportunities, including personalised 1-2-1 meetings, a vibrant drinks reception, and informal gatherings to foster meaningful connections. 

Precision Medicine Awards
Be part of an extraordinary evening of celebration, as we honour the pioneers driving precision medicine innovation.

NextGen Biomed - What to Expect Image 1
NextGen Biomed - What to Expect Image 2
NextGen Biomed - What to Expect Image 3

Key Event Highlights

An unmissable journey awaits you: From celebrated keynote speakers and insightful fireside chats, to the brand new Awards Dinner. Discover the moments that will transform your Biomarkers & Precision Medicine experience. 

2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

NGS, CLINICAL OMICS & DIAGNOSTICS 
Panel Discussion: Overcoming Multi-Omics Data Harmonisation & Analysis Challenges 

Moderator: RUSLAN SADREYEV, Director of Bioinformatics & Assistant Professor, Massachusetts General Hospital
Panellists: 
ARIDAMAN PANDIT, Senior Principal Research Scientist, AbbVie 
FELIX FRANCIS, Sr. Manager, Data Management and Analytics Technology Lead, Takeda 
LUCA PINELLO, Associate Professor of Pathology, Harvard Medical School 
MEDHI DAMAGHI, Assistant Professor & Group Leader, Stony Brook University 
SIMONA CRISTEA, Head of Genomics Data Science & AI, Dana-Farber Cancer Institute 
LUCAS SCHÜTZ, Chief Operational Officer, AriadneAI 

SINGLE CELL 
Presentation: Comparative Insights In Single Cell RNA-seq & Advances In Large-Scale Multimodal Profiling

ZORA MODRUSAN, Senior Director of NGS, Genentech

SPATIAL MULTI-OMICS
Panel Discussion: Guiding Immuno-Oncology Breakthroughs With Spatial Biology

Moderator: ALINA AINBINDER, Scientific Associate Director, Oncology, Takeda
Panellists:
JASMINE PLUMMER, Director, St. Jude Children’s Research Hospital
JIA-REN LIN, Technical Director of Tissue Imaging Platform, Harvard Medical School
NIR BEN CHETRIT, Assistant Professor, Weill Cornell Medicine
COLLES PRICE, Scientific Associate Director, Takeda
YASSER RIAZALHOSSEINI, Associate Professor & Head of Cancer Genomics, McGill University

CROSS PROGRAMME  
Breakfast Roundtables - with topics including 

•   The Potential Of Multi-Omics In Cell & Gene Therapies
•    New Frontiers In Liquid Biopsies
•    Integrating Single Cell Data Across Samples
•    Overcoming Cell Segmentation Challenges In Multiplex Immunofluorescence Biomarker Imaging
•    Single Cell Multi- Omics Integration– From The Pharma Perspective
•    Safety Biomarkers In The Age Of Spatial Biology
•    Harnessing Spatial Transcriptomics In Immunoscience
•    Spatial Analysis Of Cancer Data
•    Advancing Spatial Biology Using The Complexities Of Immune Cell Interactions In

NextGen Biomed 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Who is Speaking at NextGen Biomed 2025?

Anna Perdrix
CEO,
Sixfold Bioscience
Fernando Albericio
Professor,
University of KwaZulu-Natal
Kelly Loyet
Distinguished Scientist,
Genentech
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Livija Deban
Chief Scientific Officer,
Prokarium
Maria Koufali
Director,
UK Vaccine Innovation Pathway
Marta Amaral
Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Nazneen Dewji
Chief Executive Officer,
Cenna Biosciences
Philip Beer
CSO,
Step Pharma
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Sudhir Agrawal
Founder and President,
ARNAY Sciences
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Aaron John Balana
Scientist III,
Genentech
Aikaterini Gatsiou
Assistant Professor,
Lancaster University
Alain Wagner
Research Director,
Strasbourg University
Alastair Lawson
Vice President,
UCB
Alessandra Tolomelli
Program Director in UNIBO for Erasmus Mundus Master “Chemical Innovation and Regulation” - EMMCHIR,
Alma Mater Studiorum – Università di Bologna
Alessandro Gori
Group Leader,
National Research Council of Italy
Alexandria Cogdill
Head of Strategic Initiatives, Global Business Development,
Daiichi Sankyo, Inc
Álvaro Enríquez García
Medicinal Chemist,
Eli Lilly
Amita Vaidya
Principal Scientist,
Sanofi
Ammar Ahmed
Senior Scientist,
Imperial College London
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Anand Kumar
Senior Scientist,
Sanofi
Andreas Reichel
Vice President, Head of Research Pharmacokinetics,
Bayer
Andreas Midbøe Hoff
Head of In Silico & AI Department,
Nykode
Andrew Slee
Chief Operating Officer,
AgenusBio
Andrew Jamieson
Professor Of Chemical Biology ,
University of Glasgow
Andrew Buchanan
Principal Scientist: Biologics Engineering,
AstraZeneca
Andrew Creese
Associate Director,
Immunocore
Andri Vasou
Head of Platform Development,
Bioarchitech
Aneesh Karatt Vellatt
Chief Scientific Officer, Board Director,
Maxion therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group Leader of PeptLab,
University of Florence
Annelise Vuidepot
Chief Technology Officer,
Immunocore
Antonio Postigo
Chief Scientific Officer,
Stratosvir
Aswin Doekhie
Chief Technology Officer,
EnsiliTech
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Bassam Hallis
Deputy Director of Research and Evaluation,
UK Health Security Agency
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bernard Maillere
Head of Laboratory,
CEA
Bjorn Onfelt
Professor of Applied Physics,
Royal Institute of Technology
Brian Schanen
Global Head of Biomarkers,
Sanofi
Caleb McClain
Chief Executive Officer,
ANUNA (AI+BIO)
Callum Scott
Head of Development,
Scancell
Carla Vinals
Vice President, Global Regulatory Product Strategy,
Moderna Therapeutics
Carol Sze Ki Leung
Principal Investigator ,
Ludwig Institute, Oxford University
Charlotte Vernhes
Scientific and Medical Affairs Director,
Vaccines Europe
Christian Garde
Director,
Evaxion Biotech
Christopher Scott
Professor,
Queen's University Belfast
Dan Hardy
CEO,
Microsol
Daniel Larocque
Innovation Lead, Innovation and Emerging Science,
Sanofi Vaccines
Daniel Fonseca
Senior Research Scientist I ‑ Experimental Immunology,
Immunocore
Daniel Sejer Pedersen
Chemical Development Specialist,
Novo Nordisk A/S
David Craik
Professor,
The University of Queensland
David Brockwell
Professor,
University of Leeds
David Pejoski
Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,
Adoram Therapeutics
David Wraith
Professor,
UNIVERSITY OF BIRMINGHAM
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Deniz Eris
Principal Scientist,
Novartis
Dorothy Bray
Senior Executive,
Celtic Biotech
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Director Analytical Development & Quality Control,
Byondis B.V.
Elisa Marelli
Research Scientist,
Scancell
Elizabeth Boulter
Senior Scientist,
AstraZeneca
Erik Vernet
Vice President - Scientific Data Registration,
Novo Nordisk
Ernst Weber
Head of Molecular Design & Engineering & Bayer Science Fellow,
Bayer AG
Etienne Matous
Head of Lead Optimisation,
Iginnovate
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Roche
Francisca Wollerton
Senior Director,
AstraZeneca
Gabriel Wong
Senior Director Physician, Clinical Research, Immunology,
AstraZeneca
Georgios Skretas
Director,
Biomedical Sciences Research Center "Alexander Fleming"
Giulio Russo
Senior Scientist,
Merus
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Helene Kaplon
Translational Scientist,
Servier
Henry Maun
Staff Scientist,
Genentech
Hester Van Zeeburg
Project Manager Immune & Disease Monitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Itishri Sahu
Program Lead Therapeutics,
Ziphius Vaccines
Iulia Oita
CMC Manager,
Ziphius Vaccines
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jennifer Percival-Alwyn
Scientific Leader,
GSK
John Maher
Chief Scientific Officer,
Leucid Bio
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Joost Uitdehaag
Head of Biology,
Crossfire Oncology B.V.
Jörg Wischhusen
Professor,
University Hospital Würzburg
Jutta Eichler
Professor Medicinal Chemistry,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Kate Smith
Senior Director, Head of UK Protein and Cell Sciences,
GSK
Ken Chow
Health Tech Counsel,
Flanders Investment & Trade
Kerry Chester
Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,
The Antibody Society
Kevin Maskell
Research Director,
Bioarchitech
Knud Jørgen Jensen
Professor,
Copenhagen University
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Laura Starkie
Director,
UCB
Laura Collins
Director Bioinformatics,
Immunocore
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lucia Ferrazzano
Junior Assistant Professor,
University of Bologna
Lukas Pekar
Lab Head,
Merck
Mads Hald Andersen
Professor,
National Centre For Cancer Immune Therapy (CCIT-dk)
Mani Mudaliar
Director, Quantitative Biomarkers,
Recursion
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
MSD
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Mark Eccleston
CEO,
Valirx Plc
Markus Templin
Head Of Cellular & Molecular Biology,
NMI
Martina Ochs
Project Leader,
CEPI
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Micaela Graglia
Analytical Chemist, Molecular Design,
Silence Therapeutics
Michael Delaney
Principal Scientist,
Novo Nordisk
Mihaela Bozic
Scientist,
T-Therapeutics Ltd
Mikhail Kuravsky
Principal Scientist,
UCB
Nathan Alves
Research Director,
Indiana University School of Medicine
Nesrine Chakroun
Associate Director,
Merus NV
Nicola Ferrari
Director,
AstraZeneca
Norbert Furtmann
Head of AI Innovation NANOBODY® Platform,
Sanofi
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Owen Vickery
Associate Principal Scientist,
AstraZeneca
Patricia Alves
Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,
Instituto de Biologia Experimental e Tecnológica
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Pawel Stocki
Vice President,
Ossianix
Peter Sondermann
Chief Executive Officer,
Tacalyx GmbH Privacy Policy Imprint
Prasun Chakraborty
Chief Executive Officer and Founder,
Genevation LTD
RaJ Mehta
CEO,
Adendra Therapeutics
Raymond Tesi
President & Chief Executive Officer,
InMune Bio
Reeta Daswani
Senior Scientist II,
Sixfold Biosciences
Rita Martello
Scientific Director, NBE DMPK Lead,
Merck KGaA
Robert Andrews
Biotech IP Strategist,
Mewburn Ellis LLP
Rodrigo Abreu
Principal Scientist,
LifeArc
Russell LaMontagne
CEO,
BITT
Sagar Kathuria
Sr. Scientist, Protein Engineering I,
Sanofi
Sandor Batkai
Freelance Consultant,
Batkai.Condulting (ex-Cardior Pharmaceuticals)
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
Roche
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Santiago Parpal
Principal Scientist,
Sprint Bioscience
Sarah Stuart
High Throughput Characterisation Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saurabh Sen
Associate Director, Cell Line Development, Mammalian Platform Biologics,
Sanofi
Sebastian Sten
Associate Principal Scientist,
AstraZeneca
Sevim Ozgur Bruderle
Lab Head,
Sanofi
Shao-An Xue
Senior Scientist,
University College London
Silvia Crescioli
Business Intelligence Creator,
The Antibody Society
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Simone Friedrich
Director Antibody Discovery & Development,
iOmx Therapeutics
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sonja Merkas
Founder, Creator & Doer,
Livinovea
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Associate Director of Chemistry,
Nucleic Acid Therapy Accelerator, Medical Research Council (UKRI)
Stefan Zielonka
Senior Director, Global Head of Antibody Discovery & Protein Engineering,
Merck KGaA
Stephen Miller
Principal Scientist,
Genentech
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & Chief Executive Officer,
Myria Biosciences
Stine Friis Thorsen
Director Clinical Development,
Evaxion Biotech
Sue Charlton
Head of Clinical Evaluation,
UKHSA
Talip Ucar
Sr. Director,
AstraZeneca
Tanya Ponomaryov
Principal scientist,
Plasticell
Thomas Kraft
Principal Scientist,
Roche
Thomas Powell
Senior Scientist,
Immunocore
Timothy Hickling
Immunogenicity Expert Scientist,
Roche
Tomasz Witkos
Associate Director,
AstraZeneca
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trevor Smith
VP,
Inovio
Ulrike Rieder
Scientific Lead,
Novartis
Vaios Karanikas
Biomarker Experimental Medicine Leader, Oncology,
Hoffmann La Roche Ltd
Vik Reebye
Head of Academic Partnerships,
MiNA Therapeutics
Vincent Dewar
Head of Immunoassay,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Walter Cabri
Professor,
Fresenius Kabi
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Senior Director - Process Chemistry & CMC,
Bicycle Therapeutics
Wolfgang Koch
Senior Scientist,
F-star Therapeutics Inc
Yann Abraham
Associate Director AI for Single Cell,
Johnson & Johnson Innovative Medicine
Yiping Wu
Senior Scientist,
AstraZeneca
Zahra Rattray
Senior Lecturer,
University of Strathclyde
Zinaida Dedeic
Senior Scientist,
University of Oxford

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

2025 Sponsors Include

GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

New Opportunities

The Start-up Zone

The start-up zone provides a unique opportunity for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals. 

It's designed for start-ups from across the biologics space, working on cutting-edge therapies, innovative platform technologies, products, and solutions and is an ideal platform to share your business plans and promote your science.

There are two options, based on the type of your organisation with prices starting from £1,500 (+VAT) for companies with own therapeutic research pipeline and registration from £3,500 (+VAT) available for companies offering solutions, services or platform technologies.

For further information and to get started submit the application form below.

Criteria:

To qualify your company must be:

  • Therapeutic Start-Up, Emerging Technology OR Service Start-Up
  • Operating No More Than 5 Years
  • 0 – 30 employees
  • Pre-Series A Funding

 

Successful applications receive:

  • 1 Full Conference Pass
  • 10-Minute Presentation Opportunity
  • 1x1m Space in Start-Up Zone
  • Logo Featured on Event Website & App as a Participating Start-Up
  • Ability to Arrange Peer to Peer Meetings via the Congress App

2025 Best Poster Presentation Competition & Award

The NextGen Biomed Best Poster Presentation Competition & Award includes the best poster presentation award and is intended to honour an outstanding individual performance for a scientific work by either an early career or established scientist, including PhD student and PostDocs.  

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
    • Open to all scientists, including students (PhD), PostDocs, and established researchers representing pharma & biotech companies and/or academic institutions  
    • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025 
    • ONLY ONE submission per person will be accepted. If authors submit multiple abstracts for consideration for the competition, only one abstract will be taken into consideration  

Applicants must follow the procedure as follows:  

  • Register and submit an abstract by 13th January 2025 using the registration link to the right on this page. Please ensure you add the poster display option on the registration page to secure your admission into the Best Poster Competition & Award
  • Once registered you will be provided with the online abstract submission form  
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)  
  • The winner with the highest scores will be announced at the Morning Networking Break on Day 3 of the event  

The poster presentations will be evaluated by everyone attending the event on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). Attendees will be allowed to cast one vote by selecting their favourite work in the poster area. All votes will be counted at the end of Day 2 at 5pm and results will be announced during the morning networking break on Day 3. .

The winner receiving the highest scores will be announced on Day 3 and will be given a trophy as well as £600 contribution towards travel & accommodation costs to attend the 2026 NextGen Biomed event. Oxford Global will also provide winners with PLUS Pass – 12 months access to our digital content platform providing access to on-demand presentations, exclusive reports and highlights.  

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Biomarkers & Precision Medicine 2025: 30 September - 01 October 2025, London, UK

Elena Miranda
Director, Non Clinical Histology,
GSK
Espen Walker
Global Head of Medical Diagnostics,
AstraZeneca
Jeroen van der Laak
Professor of Computational Pathology,
Radboudumc
Maria Orr
Head of Precision Medicine and Biosamples,
AstraZeneca
Mark Caufield
Professor,
Queen Mary University of London
Matt Brown
Chief Scientific Officer,
Genomics England
Paul van Diest
Professor and Head, Department of Pathology,
University Medical Center Utrecht
Stephanie Craig
Lecturer,
Queen's University Belfast
Svetlana Mukhina
Director Global Regulatory Affairs, CDx,
Merck Group
Virginia Savova
Senior Director, Cell Targeted Precision Medicine,
AstraZeneca
Alain Van Gool
Professor Personalized Healthcare,
Radboud University Medical Center
Amonida Zadissa
Associate Director of Informatics,
UK Dementia Research Institute
Ana Hidalgo Sastre
Director,
AstraZeneca
Antonina Mitrofanova
Associate Professor,
Rutgers University
Arman Rahman
Assistant Professor,
University College Dublin
Arthur Lewis
Director,
AstraZeneca
Azam Hamidinekoo
Associate Director,
AstraZeneca
Belinda Nedjai
Associate Professor,
Queen Mary University Of London
Bernd Wollscheid
Professor,
ETHZ
Chris Bray
Head Global Regulatory Affairs,
Merck & Cie KmG
Danny Kaye
Lead Digital Pathology Scientist,
Leeds Teaching Hospitals NHS Trust, NPIC
David Clark
Consultant Haematopathologist,
Nottingham University Hospitals NHS Trust
David Snead
Pathologist,
Histofy AI
David Krige
Head of Translational Sciences,
Accession Therapeutics
Debayan Mukherjee
Principal Scientist,
GSK
Emanuela Oldoni
Scientific Programme Manager- Biomarkers,
EATRIS
Emmanuel Valentin
Vice President, Translational Medicine,
Imcheck Therapeutics
Fan Liu
Professor,
FMP Berlin
Francesca Trapani
Scientific Director,
Boehringer Ingelheim
Gayle Marshall
Head of Biomarkers,
Catapult Medicines Discovery
Giovanna Lalli
Director,
LifeArc
Harpreet Saini
Senior Director Bioinformatics,
Astex Pharmaceuticals
Helen Graves
Principal Scientist,
Alchemab Therapeutics
Henoch Hong
Associate Director,
Merck & Cie KmG
Huw Bannister
Senior Director,
AstraZeneca
Inês Sequeira
Postdoctoral,
Queen Mary University of London
Irene Del Molino del Barrio
Principal Scientist,
GSK
James Schofield
Chief Executive Officer,
TopMD
Jan-Philipp Mallm
Head of Single Cell Open Lab, DKFZ,
DKFZ
Jean-Baptiste Lugagne
Group Leader & Assistant Professor,
Centre for Medicines Discovery
Jean-Christophe Olivo-Marin
Professor & Head of the Quantitative Image Analysis Unit,
Institute Pasteur
Jens Kieckbusch
Director,
GSK
Jim Eyles
Director,
AstraZeneca
Jimmy Bell
Professor,
University of Westminster
Jo Taylor
Founder,
METUPUK
Joanna Janus
Research Programme Manager (Early Detection and Prevention),
Cancer Research UK
Joao Pinto
Surgical Pathologist,
Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup)
Johan Luthman
Executive Vice President,
Lundbeck
Jose Izarzugaza
Director of Biomarker and MoA Insights,
Novo Nordisk
Joshua Atkins
Senior Genomic Epidemiologist,
Cancer Epidemiology Unit (CEU) - University of Oxford
Karl Smith-Byrne
Senior Molecular Epidemiologist, Cancer Epidemiology Unit (CEU),
Centre for Medicines Discovery, University of Oxford
Kazumasa Kanemaru
Postdoctoral Researcher,
Teichmann Group, Cambridge Stem Cell Institute, University of Cambridge
Kiri Granger
Chief Scientific Officer,
Monument Therapeutics
Laurent Audoly
Co-Founder,
PriveBio
Liz Harrington
Executive Director,
Astrazeneca
Mani Mudaliar
Director, Quantitative Biomarkers,
Recursion
Manuel Salto-Tellez
Professor,
The Institute of Cancer Research
Manuela Cerina
Scientific Director of Neurodegeneration,
LifeArc
Maria Laura Garcia Bermejo
Scientific Director & Co-Chair,
Ramon y Cajal Health Research Institute (IRYCIS)
Marisca Marian
Oncology Market Access Strategy Leader,
Bayer AG
Markus Schulze
Senior Scientist,
Merck & Cie KmG
Martin Isabelle
Associate Director, Tumour Profiling and Mechanistic Biology, Translational Sciences,
Adaptimmune
Matthew Humphries
Director,
NHS
Michael Zaiac
Head,
Daiichi Sankyo
Michael Cannarile
Head of Biomarkers, Early Development Oncology (EDO), Pharma Research & Development (pRED),
Roche
Miguel Souto
Director,
Idibell
Mike Messenger
Head of Regulatory Strategy,
BIVDA
Miro Venturi
Operating Partner,
ARCHIMED
Muhammad Aslam
Clinical Director,
Velindre University
Nathalie Banner
Director of Ethics,
Genomics England
Neil Humphryes-Kirilov
Associate Director,
C4X Discovery
Nitin Jain
Director, Franchise Project Management,
AstraZeneca
Olga Nissan
Chief Executive Officer,
Protica Bio
Peter Groenen
Head of Translational Science,
Cerebrum DAO
Prakash Ramachandran
Professor,
University of Edinburgh
Raffaele Adolfo Calogero
Professor,
University of Torino
Rahul Deb
Consultant Histopathologist, Lead Breast Pathologist,
University Hospitals of Derby and Burton NHS Foundation
Richard Festenstein
Clinical Professor,
Imperial College London
Roya Esat Dabestani
Precision Medicine Lead,
Innovate UK Business Connect
Sonali Natu
Clinical Lead,
Incisive Health
Thomas Jensen
Chief Executive Officer,
Allarity Therapeutics
Thomas Hach
Global Program Clinical Head,
Novartis
Valerie Taly
Group Leader,
University of Paris Descartes
Victoria Goss
Head of Early Diagnosis and Translational Group,
University of Southampton
Vihanga Pahalawatta
Director of Regulatory Affairs Companion Diagnostics,
AbbVie
Wanderson Dos Santos Trindade
Director,
Daiichi Sankyo
Wolfgang Breitwieser
Head of Molecular Biology,
Cancer Research -UK Manchester Institute

Getting There

QEII
Broad Sanctuary, London SW1P 3EE

Located in the heart of Westminster, the Queen Elizabeth II Centre is just minutes from three major Underground lines, Jubilee, District, and Circle via nearby Westminster and St. James’s Park stations. The venue is within walking distance of key National Rail stations including Charing Cross, Victoria, and Waterloo, and offers excellent connections to London City and Gatwick airports. Set opposite Westminster Abbey and close to Parliament Square, the QEII Centre is ideally placed for both business and leisure visitors. While there is no public parking on-site, Blue Badge holders may park on the forecourt (by prior arrangement), with public parking available nearby. 

By Air  

London City Airport  The QEII Centre is easily accessible from London City Airport via the DLR. Take the DLR to Bank station, then transfer to the Circle or District line to Westminster. From Westminster station, it's a short 5-minute walk to the Centre. The journey costs between £3.50 and £5, depending on time and payment method. Alternatively, a taxi will take approximately 30 minutes and cost around £40–£45, depending on traffic. 

London Gatwick Airport  Take a Thameslink train from Gatwick to London Bridge (around 35 minutes), then transfer to the Jubilee line for Waterloo or Westminster. From Westminster station, it’s just a 5-minute walk to the QEII Centre. A taxi from Gatwick typically takes 60–90 minutes, with fares ranging from £65 to £85. 

Heathrow Airport – From Heathrow Airport, take the Elizabeth Line to Bond Street, then transfer to the Jubilee line to Westminster Station, which is a short 5 minute walk to the QEII Centre. The Piccadilly Line to Hammersmith switching to the District Line to Westminster is also another route which can be taken. A taxi from Heathrow to the venue takes around 45 – 60 minutes and can cost from £40 - £80.  

By Underground and Bus 

St. James’s Park is just a four-minute walk from the Queen Elizabeth II Centre and is served by the Circle and District lines. However, please note that this station does not offer step-free access, which may be important for those with mobility needs. Alternatively, Westminster Station is approximately a five-minute walk away and provides access to the Circle, District, and Jubilee lines. Westminster is a step-free station and offers accessible routes suitable for passengers with limited mobility. 

If arriving via Westminster Station, exit through Exit 6. This leads into an underground tunnel that emerges near Parliament Square. Once at street level, continue onto Whitehall, then turn left into Parliament Square. From there, cross the road and turn right onto Broad Sanctuary. The Queen Elizabeth II Centre will be on your right, directly opposite Westminster Abbey. 

For those travelling by bus, routes 11, 88, and 148 all serve the area around Parliament Square. These buses will drop passengers either directly outside Westminster Abbey or within close proximity to it, offering convenient access to the venue. 

By Rail  

The nearest National Rail station is Charing Cross, approximately a 12-minute walk from the QEII Centre. Victoria Station is also within walking distance, taking around 14 minutes on foot, while Waterloo Station is slightly further, at about an 18-minute walk. All three stations offer excellent transport links across London and beyond. 

By Car  

Leave the A4 at the Lancaster Place/Aldwych exit and continue onto the Strand. At Trafalgar Square, take the third exit onto Northumberland Avenue. Follow it to Victoria Embankment, then turn right. Continue briefly, then turn left onto Bridge Street. At Parliament Square, bear left onto Broad Sanctuary. The Queen Elizabeth II Centre will be on your right, opposite Westminster Abbey. Nearby public parking is available.  

Parking 

The QEII Centre does not offer public car parking facilities. However, Blue Badge holders are permitted to park on the Centre’s forecourt free of charge, subject to availability. Visitors are advised to call ahead on +44 20 7798 4000 to confirm access. Disabled passengers arriving by taxi or other vehicles may also be dropped off on the forecourt. For other visitors, JustPark offers nearby parking spaces, with prices starting from £3.30. Please see here.  

 

 

 

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2026, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biomarkers & Precision Medicine 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Ready to be part of it?

Join us and be part of the movement
secure your seat now

See the full programme

Review the full list of world-class speakers, thought leadership sessions and more